Tessera Therapeutics

Venture capital mega-rounds of $100m or more have surged in 2024 and the trend has continued in December, with announcements on 19 December that Ottimo Pharma’s series A round brought in more than $14

Flagship Pioneering has more than doubled the funding it has raised since 2021 and will direct it toward building more than a dozen companies across human health, artificial intelligence and sustainab

SXSW is known for attracting celebrities from the worlds of film, music and tech, and this year drew a unique combination of medical, regulatory and entrepreneurial medtech expertise in the person of

Biotech entrepreneur Geoffrey von Maltzahn believes his company, Tessera Therapeutics , has a gene editing technology more powerful than CRISPR-Cas9, and after years of secretive lab development, is